Meredith provides operational leadership for the Global Coalition for Adaptive Research (GCAR), a nonprofit research organization founded to expedite the discovery and development of cures for patients with rare and deadly diseases, and home of GBM AGILE, an international, seamless Phase II/III response adaptive randomization platform trial in glioblastoma. Before joining GCAR, Meredith was Director of Clinical Trial Strategy at Berry Consultants, providing strategic guidance for master protocols/platform trials. Previously, Meredith was an assistant professor at the University of California, San Francisco and served as Executive Director of the I-SPY TRIALs Consortium, innovative platform trials for locally advanced breast cancer.